Led by alums from Takeda and Boston Pharmaceuticals, Hillstar Bio is working on treatments that remove harmful immune cells to relieve disease.

Prior to that, he was Senior Vice President of Global Research at Zenas BioPharma,and he held leadership roles at Boston Pharmaceuticals as Vice President of Diligence and Non-Clinical Development ...

Prior to that, he was Senior Vice President of Global Research at Zenas BioPharma,and he held leadership roles at Boston Pharmaceuticals as Vice President of Diligence and Non-Clinical Development, ...

Recursion Pharmaceuticals—a relatively small company backed by the chip giant Nvidia—is betting that its massive ...

currently with Boston Pharmaceuticals and Pfizer, which also involve 4-1BB bispecific proteins. Pfizer is developing SGN-BB228, a CD228/4-1BB candidate it inherited as part of its takeover of ...

X4 Pharmaceuticals, Inc. (XFOR) on Tuesday reported a loss of $39.8 million in its fourth quarter. On a per-share basis, the Boston-based company said it had a loss of ...

Analysts at Jefferies said that Indian pharmaceutical businesses, who depend heavily on the United States for their income, ...

BOSTON (AP) — BOSTON (AP) — X4 Pharmaceuticals, Inc. (XFOR) on Tuesday reported a loss of $39.8 million in its fourth quarter. On a per-share basis, the Boston-based company said it had a loss ...

There’s been no shortage of either in recent weeks. Plunging valuations across the biotech sector were thrust into the ...